Skip to main content
Fig. 4 | Respiratory Research

Fig. 4

From: Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)

Fig. 4

Rate of COPD exacerbations based on HCRU (a) and EXACT (b) definitions. Data are LS means and RR (CI) for the pooled ITT-exacerbations population; * p < 0.05, ** p < 0.01 vs placebo, ǂ p < 0.05 vs aclidinium; CI, confidence interval; COPD, chronic obstructive pulmonary disease; EXACT; EXAcerbations of Chronic pulmonary disease Tool; FDC, aclidinium/formoterol fixed-dose combination; HCRU, Healthcare Resource Utilisation; ITT, intent-to-treat; LS, least squares; RR, rate ratio

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us